Company intelligence / Profile preview
Acesion Pharma
Copenhagen/Ballerup, Region Hovedstaden, Denmarkacesionpharma.com ↗
- Ownership
- Private
- Employees
- ~19
- Development stage
- Other
01
Overview
Acesion has completed a Phase 2 trial for AP30663, demonstrating positive results for conversion of atrial fibrillation to normal sinus rhythm. The trial met its primary endpoint with a Bayesian analysis showing probability less than 99.9% of a true AF conversion rate greater than placebo across two doses. The safety profile was consistent with previous Phase 1 trials, with no serious adverse events reported.[8][10]
- Therapeutic areas
- Cardiovascular
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Acesion Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Acesion Pharma.